相似文献
1
Novel Imaging of Prostate Cancer with MRI, MRI/US, and PET.
Curr Oncol Rep. 2015 Dec;17(12):56. doi: 10.1007/s11912-015-0480-y.
2
Whole-Body Integrated [Ga]PSMA-11-PET/MR Imaging in Patients with Recurrent Prostate Cancer: Comparison with Whole-Body PET/CT as the Standard of Reference.
Mol Imaging Biol. 2020 Jun;22(3):788-796. doi: 10.1007/s11307-019-01424-4.
3
Integrated 68Gallium Labelled Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Magnetic Resonance Imaging Enhances Discriminatory Power of Multi-Parametric Prostate Magnetic Resonance Imaging.
Urol Int. 2018;100(2):164-171. doi: 10.1159/000484695. Epub 2018 Jan 25.
4
Integrated Ga-HBED-CC-PSMA-PET/MRI in patients with suspected recurrent prostate cancer.
Nuklearmedizin. 2017 Jun 13;56(3):73-81. doi: 10.3413/Nukmed-0850-16-09. Epub 2017 Apr 12.
5
Ga-PSMA-PET: added value and future applications in comparison to the current use of choline-PET and mpMRI in the workup of prostate cancer.
Radiol Med. 2018 Dec;123(12):952-965. doi: 10.1007/s11547-018-0929-9. Epub 2018 Aug 16.
6
Clinical performance of Ga-PSMA-11 PET/MRI for the detection of recurrent prostate cancer following radical prostatectomy.
Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):20-30. doi: 10.1007/s00259-017-3850-x. Epub 2017 Oct 14.
7
Early GA-PSMA PET/MRI acquisition: assessment of lesion detectability and PET metrics in patients with prostate cancer undergoing same-day late PET/CT.
Clin Radiol. 2017 Nov;72(11):944-950. doi: 10.1016/j.crad.2017.06.116. Epub 2017 Jul 14.
8
[PET-CT and PET-MRI of the prostate : From F-FDG to Ga-PSMA].
Radiologe. 2017 Aug;57(8):631-636. doi: 10.1007/s00117-017-0276-1.
9
Reduced Acquisition Time per Bed Position for PET/MRI Using Ga-RM2 or Ga-PSMA-11 in Patients With Prostate Cancer: A Retrospective Analysis.
AJR Am J Roentgenol. 2022 Feb;218(2):333-340. doi: 10.2214/AJR.21.25961. Epub 2021 Aug 18.
10
PET/MRI with a 68Ga-PSMA ligand for the detection of prostate cancer.
Eur J Nucl Med Mol Imaging. 2013 Oct;40(10):1629-30. doi: 10.1007/s00259-013-2489-5. Epub 2013 Jul 2.
引用本文的文献
1
Nano-Theranostics for the Sensing, Imaging and Therapy of Prostate Cancers.
Front Chem. 2022 Apr 12;10:830133. doi: 10.3389/fchem.2022.830133. eCollection 2022.
2
Positron emission tomography (PET) in primary prostate cancer staging and risk assessment.
Transl Androl Urol. 2017 Jun;6(3):413-423. doi: 10.21037/tau.2017.03.53.
3
PET imaging of recurrent and metastatic prostate cancer with novel tracers.
Future Oncol. 2016 Nov;12(21):2463-2477. doi: 10.2217/fon-2016-0270. Epub 2016 Aug 16.
4
Prostate cancer: The applicability of textural analysis of MRI for grading.
Nat Rev Urol. 2016 Apr;13(4):185-6. doi: 10.1038/nrurol.2016.33. Epub 2016 Feb 16.
本文引用的文献
1
PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2.
Eur Urol. 2016 Jan;69(1):16-40. doi: 10.1016/j.eururo.2015.08.052. Epub 2015 Oct 1.
2
Body diffusion kurtosis imaging: Basic principles, applications, and considerations for clinical practice.
J Magn Reson Imaging. 2015 Nov;42(5):1190-202. doi: 10.1002/jmri.24985. Epub 2015 Jun 26.
3
¹⁸F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer.
J Nucl Med. 2015 Jul;56(7):1003-1010. doi: 10.2967/jnumed.115.154336. Epub 2015 Jun 11.
4
Accuracy of cognitive MRI-targeted biopsy in hitting prostate cancer-positive regions of interest.
World J Urol. 2016 Jan;34(1):75-82. doi: 10.1007/s00345-015-1588-2. Epub 2015 May 17.
5
Automated prostate cancer detection using T2-weighted and high-b-value diffusion-weighted magnetic resonance imaging.
Med Phys. 2015 May;42(5):2368-78. doi: 10.1118/1.4918318.
6
A Novel ¹¹¹In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer.
J Nucl Med. 2015 Jul;56(7):1094-9. doi: 10.2967/jnumed.115.156729. Epub 2015 May 14.
7
The value of anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT in the diagnosis of recurrent prostate carcinoma: a meta-analysis.
Acta Radiol. 2016 Apr;57(4):487-93. doi: 10.1177/0284185115581541. Epub 2015 Apr 22.
8
Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
J Nucl Med. 2015 Jun;56(6):914-20. doi: 10.2967/jnumed.114.147413. Epub 2015 Apr 16.
9
Evaluation of Hybrid ⁶⁸Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy.
J Nucl Med. 2015 May;56(5):668-74. doi: 10.2967/jnumed.115.154153. Epub 2015 Mar 19.
10
MRI-targeted biopsies versus systematic transrectal ultrasound guided biopsies for the diagnosis of localized prostate cancer in biopsy naïve men.
Biomed Res Int. 2015;2015:571708. doi: 10.1155/2015/571708. Epub 2015 Jan 27.
Zotero 插件